Verastem (VSTM) Cash & Current Investments (2011 - 2026)
Verastem (VSTM) posted quarterly Cash & Current Investments of $197.8 million for Q1 2026, up 68.26% year-over-year from $117.6 million in Q1 2025, and down 3.49% quarter-over-quarter from $205.0 million in Q4 2025.
Analysis
Verastem (VSTM) Cash & Current Investments (2011 - 2026) Analysis & Trends
Verastem's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $197.8 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 68.26% year-over-year to $197.8 million; the TTM figure through Mar 2026 stood at $197.8 million (up 68.26% YoY), while the FY2025 annual figure was $205.0 million, up 130.8% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $197.8 million, down from $205.0 million in the prior quarter.
- The five-year high for Cash & Current Investments was $205.0 million in Q4 2025, with the low at $83.4 million in Q2 2024.
- The 5-year median for Cash & Current Investments is $113.2 million (2024), against an average of $130.1 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments sank 54.46% in 2024, then jumped 130.8% in 2025.
- Verastem's Cash & Current Investments stood at $92.0 million in 2022, then surged by 48.99% to $137.1 million in 2023, then sank by 35.23% to $88.8 million in 2024, then surged by 130.8% to $205.0 million in 2025, then declined by 3.49% to $197.8 million in 2026.
- Business Quant data shows VSTM's Cash & Current Investments at $197.8 million in Q1 2026, $205.0 million in Q4 2025, and $137.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 136.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 136.35 Mn |
| Mar 31, 2026 | 197.83 Mn |
| Dec 31, 2025 | 204.99 Mn |
| Sep 30, 2025 | 137.71 Mn |
| Jun 30, 2025 | 164.32 Mn |
| Mar 31, 2025 | 117.57 Mn |
| Dec 31, 2024 | 88.82 Mn |
| Sep 30, 2024 | 113.18 Mn |
| Jun 30, 2024 | 83.37 Mn |
| Mar 31, 2024 | 110.13 Mn |
| Dec 31, 2023 | 137.13 Mn |
| Sep 30, 2023 | 165.66 Mn |
| Jun 30, 2023 | 183.09 Mn |
| Mar 31, 2023 | 111.20 Mn |
| Dec 31, 2022 | 87.89 Mn |
| Sep 30, 2022 | 103.98 Mn |
| Jun 30, 2022 | 94.31 Mn |
| Mar 31, 2022 | 106.28 Mn |
| Dec 31, 2021 | 100.26 Mn |
| Sep 30, 2021 | 103.42 Mn |